No Data
XORTX Therapeutics Brief: Announcing Pricing of US$1.1 Million Registered Direct Offering
XORTX Therapeutics Brief: Announcing Acquisition of Renal Anti-Fibrotic Therapeutic Program From Vectus Biosystems
XORTX Therapeutics Issues 73,871 Shares At $1.54 In Q1 2025, Raising Net Proceeds Of $109.7K Under ATM Program
XORTX Therapeutics Brief: Initiating IND Preparation for XORLO in Gout Program
XORTX Therapeutics Announces Non-Brokered Private Placement To Raise Up To $925K Through Issuance Of Up To 1.27M Common Share Units At $0.73/Unit
XORTX Therapeutics 14% Higher in U.S. Pre-market Trading After Gaining European Patent